Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
1999-02-12
2002-08-27
Chan, Christina (Department: 1614)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007920, C436S507000, C530S324000, C530S358000, C530S413000, C536S023500
Reexamination Certificate
active
06440679
ABSTRACT:
I. FIELD OF THE INVENTION
The present invention relates to a dermatomyositis-specific auto-antigen, a DNA encoding it and a process for the preparation thereof as well as its use.
II. BACKGROUND OF THE INVENTION
Autoimmune diseases distinguish themselves by the occurrence of autoantibodies, i.e., antibodies directed against constituents of the own organism. Autoantibodies may induce damage of the organism, an organ or part of an organ thus triggering partially serious life-threatening diseases. The origination of such a disease is due to differing pathogenic mechanisms such as neutralization of antigens, e.g. hormones, blocking or stimulation of a receptor for biological active substances, e.g., autoantibodies active against the receptor of the thyroid-stimulating hormone in the case of hyperthyreosis, binding to certain cell or tissue structures accompanied by the induction of a complement-mediated inflammation, e.g., glomerulonephritis, antiautobodies active against glomerulus basement membranes. Tissues damage may also be induced by cell-mediated mechanisms (autoantibody-dependent cellular cytotoxicity) or by localized and systemic immune complex deposits after the binding of the autoantibodies to soluble antigens.
In addition to such obviously directly damaging autoantibodies, a plurality of autoantibodies active against blood, cell or tissue constituents occur in man, to which a tissue-damaging part cannot be assigned yet clearly by now. The group of rheumatic diseases, particularly the inflammatory rheumatic diseases to which the collagen diseases are attributed, is characterized by the occurrence of numerous autoantibodies. They react, e.g., with antigens of the cell nucleus such as double-stranded DNA, single-stranded DNA, RNA, histones, non-histone proteins, ribonucleoproteins, chromosome-associated antigens, e.g., centromeres or spindle apparatus, or with antigens which are expressed only in certain phases of the cell cycle, e.g., cycline.
The above autoantibodies are found in the case of diseases such as lupus erythematodes, Sjögren's syndrome, mixed connective tissue disease, polymyositis, dermatosclerosis, CREST syndrome, Wegener's granulomatosis and dermatomyositis. They are usually detected by reaction with nuclear extracts from thymocytes of calves or rabbits. Due to this, a differential diagnosis of these diseases, particularly of dermatomyositis, is, however, not possible. But such a diagnosis is a precondition for the selection of treatment.
Therefore, it is the object of the present invention to provide means by which dermatomyositis can be detected by way of differential diagnosis.
III. SUMMARY OF THE INVENTION
The present invention relates to a dermatomyositis-specific auto-antigen, a DNA encoding it and a process for the preparation thereof as well as its use.
REFERENCES:
patent: WO A 92 04472 (1992-03-01), None
Altschul et al., 1990, “Basic Local Alignment Search Tool,”J. Mol. Biol.215:403-410.
Bairoch, A., 1991, “Prosite: a dictionary of sites and patterns in proteins,”Nucleic Acids Res. 19:2241.
Frohmann et al., 1988, “Rapid production of full-length cDNAs from rare transcripts: Amplification using a single gene-specific oligonucleotide primer,”Proc. Natl. Acad. Sci. U.S.A.85:8998-9002.
Ge et al., 1994, “The Major Antigenic Component of the Mi-2 Autoantigen of Dermatomyositis,” 58th National Scientific Meeting of the American College of Rheumatology and the 29th National Scientific Meeting of the Association of Rheumatology Health Professionals, Minneapolis, Minnesota, USA, Oct. 23-27, 1994.Arthritis & Rheumatism37:1147.
Ge et al., 1995, “Molecular Analysis of a Major Antigenic Region of the 240-kD Protein of Mi-2 Autoantigen,”J. Clin. Invest.96:1730-1737.
Nilasena et al., 1990, “Molecular Cloning of the Dermatomyositis (DM)-Associated Mi-2 Antigen,” 54th Annual Meeting of the American College of Rheumatology, Seattle, WA, USA, Oct. 27-Nov. 1, 1990. Arthritis Rheum. 33(9 Suppl.).
Nilasena et al., 1995, “Analysis of the Mi-2 Autoantigen of Dermatomyositis,”Arthritis & Rheumatism38:123-128.
Seelig et al., 1995, “The Major Dermatomyositis Specific Mi-2 Autoantigen is a Presumed Helicase Involved in Transcriptional Activation,”EMBL Datenbank ZugangHSMI2218 Zugriffsnummer:X86691.
Studier et al., 1990, “Use of T7 RNA Polymerase to Direct Expression of Cloned Genes,”Methods Enzymol.185:60-89.
Renz Manfred
Seelig Hans Peter
Chan Christina
Huynh Phuong N.
Pennie & Edmonds LLP
Privates Institut fur Immunologie und Molekulargenetik GmbH
LandOfFree
Dermatomyositis-specific auto-antigen does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dermatomyositis-specific auto-antigen, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dermatomyositis-specific auto-antigen will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2912467